Rapid detection of the epidermal growth factor receptor mutation in non-small-cell lung cancer for analysis of acquired resistance using molecular beacons.
A secondary mutation (T790M) in epidermal growth factor receptor (EGFR) is a hallmark of acquired resistance to EGFR inhibitors used to treat non-small-cell lung cancer (NSCLC). Therefore, identifying the T790M mutation is crucial to guide treatment decisions. Given that DNA sequencing methods are time-consuming and insensitive, we developed and investigated the feasibility of using molecular beacons for the detection of the T790M mutation in EGFR. A molecular beacon complementary to the region of the secondary EGFR mutation (T790M) was designed and used in NSCLC samples bearing drug-sensitive and -resistant EGFR mutations. For a rapid and simple assay, we attempted to use the molecular beacon with real-time PCR and in situ fluorescence imaging. The ability of the designed molecular beacon to specifically detect the T790M mutation of EGFR was tested for samples from two patients with drug resistance and compared with conventional DNA sequencing methods. The molecular beacon successfully detected the T790M mutation in patient samples with drug resistance. The sensitivity of the molecular beacon, which detected as little as 2% of genomic DNA from the drug-resistant cells (H1975), was much higher than direct sequencing. Furthermore, in situ fluorescence imaging with the molecular beacon gave rise to a distinguishable signal for the T790M mutation in drug-resistant cells. The molecular beacon-based approach enabled rapid and sensitive detection of the EGFR mutation (T790M) in NSCLC with in situ fluorescence imaging, which can be directed to determine various treatment options in patients with cancer.
Oh
Young-Hee
YH
Department of Biological Sciences, KAIST (Korea Advanced Institute of Science and Technology), Daejon, Korea.
Kim
Youngwook
Y
Kim
Young-Pil
YP
Seo
Soo-Won
SW
Mitsudomi
Tetsuya
T
Ahn
Myung-Ju
MJ
Park
Keunchil
K
Kim
Hak-Sung
HS
D001483:Base Sequence; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics*; D045744:Cell Line, Tumor; D017931:DNA Primers; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000235:genetics*; D005453:Fluorescence; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics*; D009154:Mutation; D016133:Polymerase Chain Reaction
D017931:DNA Primers; D066246:ErbB Receptors
Clin Cancer Res. 2009 Apr 1;15(7):2552-8
19318484
Cancer Res. 2007 Aug 15;67(16):7807-14
17699786
J Mol Diagn. 2006 Jul;8(3):335-41
16825506
Cancer. 2004 Jul 1;101(1):3-27
15221985
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):751-8
16467085
Cancer Sci. 2006 Jul;97(7):642-8
16827805
Science. 2004 Jun 4;304(5676):1497-500
15118125
Clin Chim Acta. 2006 Jan;363(1-2):48-60
16111667
Methods Mol Med. 2007;132:125-33
17876081
Nucleic Acids Res. 2005 Sep 28;33(17):5394-403
16192569
Proc Natl Acad Sci U S A. 1999 May 25;96(11):6171-6
10339560
N Engl J Med. 2005 Jul 14;353(2):123-32
16014882
Anal Chem. 2001 Nov 15;73(22):5544-50
11816586
Nature. 2007 Dec 20;450(7173):1235-9
18097410
Clin Cancer Res. 2006 Jan 1;12(1):43-8
16397022
Nat Biotechnol. 1998 Jan;16(1):49-53
9447593
J Virol Methods. 2008 Apr;149(1):153-62
18281103
Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5385-90
17875767
Analyst. 2005 Jul;130(7):1002-5
15965520
PLoS Med. 2005 Mar;2(3):e73
15737014
N Engl J Med. 2004 May 20;350(21):2129-39
15118073
Cancer Res. 2005 Mar 1;65(5):1909-17
15753390
Clin Cancer Res. 2007 Sep 1;13(17):4974-83
17785547